JOHNSON v. MACLEODS PHARMA USA, INC.

CourtDistrict Court, D. New Jersey
DecidedNovember 7, 2019
Docket1:19-cv-07856
StatusUnknown

This text of JOHNSON v. MACLEODS PHARMA USA, INC. (JOHNSON v. MACLEODS PHARMA USA, INC.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
JOHNSON v. MACLEODS PHARMA USA, INC., (D.N.J. 2019).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

CHERYL B. JOHNSON, 1:19-cv-7856-NLH-JS Plaintiff, MEMORANDUM v. OPINION & ORDER

MACLEODS PHARMA USA, INC. and SOUTH JERSEY BEHAVIOR HEALTH,

Defendants.

APPEARANCES:

CHERYL B. JOHNSON 506 SOUTH WHITEHORSE PIKE APARTMENT H201 STRATFORD, NJ 08084

Appearing pro se.

HILLMAN, District Judge

WHEREAS, Plaintiff Cheryl Johnson (“Plaintiff”), appearing pro se, has filed a complaint against two defendants; and WHEREAS, Plaintiff alleges that that she suffered adverse side effects after taking a prescribed medication called Olanzapine; and WHEREAS, Plaintiff further alleges that the physicians at South Jersey Behavior Health prescribed her Olanzapine; and WHEREAS, Plaintiff further alleges that “4 years after taking [this] medicine, [she is suffering from] bad loud noises” (ECF No. 1 at 5); and WHEREAS, Plaintiff further alleges that the “medicine caused [her] to hum” and that “when [she] talk[s], eat[s] and walk[s] . . . [she] hum[s] all the time off and on[,] 24 hours a

day.” (Id. at 6); and WHEREAS, Plaintiff seeks reimbursement for unspecified medical bills and an award of $400,000. (Id.); and WHEREAS, Plaintiff has filed an application to proceed without prepayment of fees (“in forma pauperis” or “IFP” application), and pursuant to 28 U.S.C. § 1915(a)(1), a court may allow a litigant to proceed without prepayment of fees if she submits a proper IFP application; and WHEREAS, although § 1915 refers to “prisoners,” federal courts apply § 1915 to non-prisoner IFP applications, Hickson v. Mauro, 2011 WL 6001088, *1 (D.N.J. 2011) (citing Lister v. Dept. of Treasury, 408 F.3d 1309, 1312 (10th Cir. 2005) (“Section

1915(a) applies to all persons applying for IFP status, and not just to prisoners.”) (other citations omitted); and WHEREAS, the screening provisions of the IFP statute require a federal court to dismiss an action sua sponte if, among other things, the action is frivolous or malicious, or if it fails to comply with the proper pleading standards, see 28 U.S.C. § 1915(e)(2)(B)(i)-(iii); Ball v. Famiglio, 726 F.3d 448, 452 (3d Cir. 2013); Martin v. U.S. Department of Homeland Security, 2017 WL 3783702, at *1 (D.N.J. August 30, 2017) (“Federal law requires this Court to screen Plaintiff’s Complaint for sua sponte dismissal prior to service, and to dismiss any claim if that claim fails to state a claim upon

which relief may be granted under Fed. R. Civ. P. 12(b)(6) and/or to dismiss any defendant who is immune from suit.”); and WHEREAS, pro se complaints must be construed liberally, and all reasonable latitude must be afforded the pro se litigant, Estelle v. Gamble, 429 U.S. 97, 107 (1976), but pro se litigants “must still plead the essential elements of [their] claim and [are] not excused from conforming to the standard rules of civil procedure,” McNeil v. United States, 508 U.S. 106, 113 (1993) (“[W]e have never suggested that procedural rules in ordinary civil litigation should be interpreted so as to excuse mistakes by those who proceed without counsel.”); Sykes v. Blockbuster Video, 205 F. App’x 961, 963 (3d Cir. 2006) (finding that pro se

plaintiffs are expected to comply with the Federal Rules of Civil Procedure); and WHEREAS, the Court finds that Plaintiff’s complaint is deficient for several reasons; and WHEREAS, first, and as a threshold matter, the Court is unable to determine the asserted basis for the Court’s exercise of subject matter jurisdiction. Federal Rule of Civil Procedure 8(a) provides that “[a] pleading that states a claim for relief must contain . . . a short and plain statement of the grounds for the court’s jurisdiction.”; and WHEREAS, diversity jurisdiction, 28 U.S.C. § 1332, does not apply as, according to the complaint, all parties are citizens

of New Jersey (ECF No. 1 at 1, 3); and WHEREAS, the complaint suggests that the Court has subject matter jurisdiction because the Government is both a plaintiff and defendant in this action, and that the Court otherwise has federal question jurisdiction because issues of “Federal Constitutional [and] Food and Drug administration (FDA) Law” are at issue. (Id. at 4); and WHEREAS, the Government is not a party to this action, and Plaintiff has not identified the basis for asserting that her claims arise under the Constitution. Moreover, Plaintiff does not expand upon her purported FDA claim or otherwise explain what federal law governs her allegations; and

WHEREAS, the complaint is otherwise void of allegations that would suggest this Court has subject matter jurisdiction; and WHEREAS, furthermore, Rule 8(a)(2) requires a complaint contain “a short and plain statement of the claim showing that the pleader is entitled to relief”; and WHEREAS, the civil cover sheet suggests that this matter sounds in contract-based product liability, health care product liability, and the Family and Medical Leave Act. (Id.); and WHEREAS, Plaintiff has not alleged any facts relating to the Family and Medical Leave Act; and WHEREAS, Plaintiff has not stated a prima facie case for product liability, or any other cause of action;1 and

WHEREAS, while Plaintiff has identified two defendants in the caption of the complaint, Plaintiff fails to explain how either defendant is connected to this action; and WHEREAS, the Court will grant Plaintiff an opportunity to file an amended complaint to correct the above-referenced

1 In New Jersey, the Product Liability Act (PLA), codified at New Jersey Statute Annotated 2A:58C, et seq., governs product liability actions. Three causes of action are established under the PLA, namely, claims for design defect, manufacturing defect, or warnings defect. Roberts v. Rich Foods, Inc., 654 A.2d 1365, 1370 (N.J. 1995). The standard of liability is that the product “was not reasonably fit, suitable or safe for its intended purpose.” Cornett v. Johnson & Johnson, 998 A.2d 543, 562 (N.J. Super. Ct. App. Div. 2010).

To prove a defect, a plaintiff must be able to show that: (1) the product was defective; (2) the defect existed when the product left the hands of the defendant; and (3) the defect caused the injury to a reasonably foreseeable user. McGarvey v. G.I. Joe Septic Service, Inc., 679 A.2d 733, 740 (N.J. Super. Ct. App. Div. 1996).

The complaint is entirely void of allegations relevant to any of these factors. Plaintiff has not alleged the drug at issue was defective, but rather only that she suffered a side effect from taking it. Moreover, Plaintiff fails to tether either of the defendants to the harm she allegedly suffered.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Estelle v. Gamble
429 U.S. 97 (Supreme Court, 1976)
McNeil v. United States
508 U.S. 106 (Supreme Court, 1993)
Lister v. Department of Treasury
408 F.3d 1309 (Tenth Circuit, 2005)
Dawn Ball v. Famiglio
726 F.3d 448 (Third Circuit, 2013)
Roberts v. Rich Foods, Inc.
654 A.2d 1365 (Supreme Court of New Jersey, 1995)
Sykes v. Blockbuster Video
205 F. App'x 961 (Third Circuit, 2006)
McGarvey v. G.I. Joe Septic Service, Inc.
679 A.2d 733 (New Jersey Superior Court App Division, 1996)
Cornett v. Johnson & Johnson & Cordis Corp.
998 A.2d 543 (New Jersey Superior Court App Division, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
JOHNSON v. MACLEODS PHARMA USA, INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/johnson-v-macleods-pharma-usa-inc-njd-2019.